To ask the Scottish Government, in the light of the US National comprehensive clinical updated guidelines on using F-18 fluviclovivine (Axumin) in diagnostic imaging in men with recurrent prostate cancer, whether it will recommend that clinicians should consider using Axumin in positronic emission tomography, computed tomography or magnetic resonance imaging in helping to determine the best treatment. The Scottish Health Technologies Group (SHTG) assesses the effectiveness and proven benefit to patients of new technologies, and they advise NHS Scotland where there is a convincing evidence base.